Journal article

Perceptions of Doppler ultrasound for rheumatoid arthritis disease activity assessment and education

Fredrick Joshua, Christine Bailey, Mona Marabani, Evange Romas, Raymond White, Peter Wong



AIM: The aim of this qualitative study was to report the findings of the Defining rheumatoid arthritis progression using Doppler Ultrasound in Clinical practice (DEDUCE) Medical Practice Activity, which was developed to facilitate the utilization of Doppler ultrasound (DUS) by Australian rheumatologists in the treatment of patients with rheumatoid arthritis (RA). METHOD: Twenty-one rheumatologists recruited a total of 80 patients with RA in Disease Activity Score of 28 joints (DAS28) remission for DUS assessment and completed a pre- and post-activity questionnaire assessing their experience with DUS, as well as a 6-month follow-up questionnaire. Rheumatologists discussed DUS results with pat..

View full abstract


Funding Acknowledgements

AbbVie contributed to the design, implementation, intellectual content and funding of the DEDUCE Medical Practice Activity. This study was funded by AbbVie Australia. The sponsor reviewed the final manuscript before submission. Statistical analyses were performed by Annie Solterbeck from Statistical Revelations and funded by AbbVie Australia. The authors acknowledge that editorial assistance in preparing the manuscript was provided by Adrianna Kalous, PhD, and Hazel Palmer, CMPP, of Scriptix Pty Ltd; this contribution was funded by AbbVie Australia. Fredrick Joshua has served as a consultant for AbbVie, Schering-Plough, Servier, Pfizer, MSD, Roche, Janssen, Sanofi, UCB and BMS. Christine Bailey is an employee (Medical Scientific Liaison) of Abbvie Australia. Mona Marabani has served as a consultant for AbbVie, BMS and Novartis, and as an investigator in clinical trials for AbbVie, Roche and Daiichi-Sankyo, and has received conference or travel support from Pfizer, BMS, Roche and UCB. Evange Romas has served as a consultant for AbbVie, UCB and Amgen, has received research funding from AbbVie, UCB, Servier and Amgen, and has received speaker fees from AbbVie and Amgen. Raymond White has received an honorarium from AbbVie and has received conference support from AbbVie, BMS, Janssen, Roche and UCB. Peter Wong has served as an investigator in clinical trials for Abbott, Celgene, Roche, Daiichi-Sankyo and UCB, has received conference or travel support from AbbVie, Servier, Roche, BMS and Pfizer, has received speaking and education honoraria from Amgen, Novartis and Servier, has received nurse support funding from AbbVie, Actelion and Roche, and has received research grants from BMS and Pfizer.